Why brain tumor drugs often fail to reach the tumor
Original title: Targeting Kinase Signaling in Glioblastoma: Structural Optimization, Blood-Brain Barrier Dynamics and Combinatorial Translational Strategies.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This looks across many earlier studies rather than running a new one.
This is a review of past studies and ideas, not a new result.
The short version
Experts looked at why one type of glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary drug keeps falling short, and what might help.
What was studied. This is a review paper, not a new study. Experts read past work on small drugs called kinase inhibitors for glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary, a brain cancer. They looked at why these drugs have not helped much in people.
What they found. The brain has a barrier that keeps many drugs out. Pumps in the brain also push these drugs back out. The review points to trials of paxalisib and osimertinib that did not work. It says a tumor can switch to other growth paths when only one path is blocked. The authors say drugs that hit more than one target, or drugs used together, may hold up better.
What this means, and what it doesn't
What it could mean: This does not change your care today. It helps explain why some past drugs did not work. It points to how researchers might design better ones.
What it doesn't mean: This does not mean a new treatment is ready. Nothing new was tested in people here. It is a look back at past work plus ideas for the future. Those ideas are still far from everyday care. It is not a promise of a cure.
Source: PubMed, July 24, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.